Aminooxyacetate (AOA), an inhibitor of transaminase activity, abrogates the alanine aminotransferase glutamic-pyruvic transaminase 1 (GPT1) activity and effectively reduces the level of intracellular ATP in HCC. The gene discussed is GPT; the disease is hepatocellular carcinoma.